Jie Xiao

Peking University People's Hospital, Peping, Beijing, China

Are you Jie Xiao?

Claim your profile

Publications (5)14.82 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To screen the cardiac troponin T (TNNT2) mutations in Chinese patients with hypertrophic cardiomyopathy (HCM) and to analyze the potential link between the genotype and the phenotype. Clinical features of 100 probands with HCM and some family members were evaluated, 200 unrelated normal subjects served as control. The exons and flanking introns of TNNT2 were amplified with PCR and direct sequencing was used to screen TNNT2 mutations/polymorphisms. Two novel missense mutations were detected in 2 HCM patients: R92W and R286H. These 2 mutations were not found in 200 non-HCM controls. A five-basepair insertion/deletion polymorphism in intron 3 of TNNT2 was identified in this HCM cohort but was not related to the phenotype. Two missense mutations, R92W and R286H, were found in 2/100 patients with HCM, TNNT 2 mutation is relatively low in Chinese patients with HCM.
    No preview · Article · Oct 2011 · Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases]
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives Some studies suggested a possible role for hepatitis C virus (HCV) in the pathogenesis of cardiovascular diseases (CVD). N-terminal pro-brain natriuretic pepetide (NT-proBNP) has been proposed to be a neurohumoral marker of cardiovascular risk. Few prior studies have evaluated such levels in HCV infection. Accordingly, the objectives of the present study were to investigate circulating levels of NT-proBNP and their relevance in patients with HCV infection. Methods We collected 131 HCV-infected patients and 131 age and gender matched healthy individuals from January 2006 to October 2007 in China. Demographics, clinical data were collected and circulating NT-proBNP was analysed, and 63 of patients were also consecutively evaluated with echocardiography. Results The level of serum NT-proBNP was higher in HCV-infected patients compared with controls (76.62 fmol/ml vs 51.83 fmol/ml, p<0.001, geometric means), even in HCV-infected patients without cardiovascular abnormalities (CVD history and /or abnormalities of ECG) NT-proBNP also increased (63.46 fmol/ml vs 48.14 fmol/ml, p=0.015, geometric means). A NT-proBNP level in the highest tertile was associated with a higher risk of cardiovascular abnormalities, with OR of 17.91 (95% CI, 3.71 to 86.47). MVE/MVA, LVEF and FS were significantly lower among patients in the highest NT-proBNP tertile, whereas MVA was higher. In addition, compared with normal values of healthy Chinese population (39.35%±4.26%), the value of FS (36.76%±5.50%, p=0.015) was lower in patients whose serum NT-proBNP level was higher than median of controls (>56.17 fmol/ml, n=37). Conclusions HCV infected individuals had higher NT-proBNP levels than age matched controls, which show a possible cardiac functional evidence for a pathogenic link between HCV and CVD. The finding is consistent with an increased incidence of HCV or HCV antibody described in some CVD patients.
    Preview · Article · Nov 2010 · Heart (British Cardiac Society)
  • [Show abstract] [Hide abstract]
    ABSTRACT: To screen the MYBPC3 gene mutations in Han Chinese patients with hypertrophic cardiomyopathy (HCM). Sixty-six patients with HCM were enrolled for the study. The exons in the functional regions of MYBPC3 were amplified with PCR and the products were sequenced. Four novel mutations and four common polymorphisms were identified in this patient cohort. A Lys301fs mutation in exon10 was evidenced in a H30, and when he was 47 years old, he had the chest tightness, shortness of breath with septal hypertrophy of 18.7mm; a Asp463stop mutation in exon17 was detected in a H48, he was 24 years old 24-year-old when a medical examination showed ventricular septal hypertrophy of 15.4 mm; both Gly523Arg mutation in exon18 and Tyr847His mutation in exon26 were found in a H53 with onset age 36 years old, feeling chest tightness after excise and his ventricular septal hypertrophy was 27 mm that time. MYBPC3 mutations occurred in 4.5% patients in this cohort. These mutations were not found in 100 non-HCM control patients. MYBPC3 mutation is presented in a small portion of Han Chinese patients with HCM.
    No preview · Article · Aug 2009 · Zhonghua xin xue guan bing za zhi [Chinese journal of cardiovascular diseases]
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of study is to investigate the effect of nifedipine on viral myocarditis in an animal model. Four-week-old male DBA/2 mice were inoculated with 2 pfu of encephalomyocarditis virus (EMCV) and randomized to nifedipine (n=10) or control (n=10) group. The control group was fed by regular chow and the nifedipine group contained 0.01% of nifedipine. Mast cell density was counted, and expressions of messenger RNAs of stem cell factor (SCF), matrix metalloproteinases (MMPs), pro-collagen I, mast cell proteases, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) were evaluated by RT-PCR. The area of myocardial necrosis was smaller in the nifedipine vs the control group (mean+/-SD, 1.2+/-1.3% vs 3.8+/-1.8%, respectively, P<0.005). The mast cell density (count/mm(2)) was lower in the nifedipine vs the control group (mean+/-SD, 0.23+/-0.16 vs 1.08+/-0.45, respectively, P<0.0005). The expressions of MMPs, mast cell proteases, TNF-alpha, IL-6, SCF and pro-collagen I were lower in the nifedipine group than in the control group (P<0.05). Nifedipine inhibited the activation of various participants in inflammatory and immune reactions in EMCV myocarditis.
    No preview · Article · Jun 2009 · Life sciences
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inflammation contributes to increased cardiovascular morbidity and mortality associated with activation of the renin-angiotensin-aldosterone system. The aim of this study was to investigate whether eplerenone, a selective aldosterone receptor antagonist, has anti-inflammatory effects on viral myocarditis. Four-week-old inbred male DBA/2 mice were inoculated intraperitoneally with 10 plaque-forming units (pfu) of the encephalomyocarditis (EMC) virus. Mice were fed with standard chow (control) or with chow containing 2.5 mg/kg of eplerenone, starting either on day 0 (inoculation) or day 7. Survival at 28 days was significantly higher in the mice which started eplerenone treatment on day 0 (35 vs. 15% in controls, each n = 40, P < 0.05). The area of myocardial fibrosis on day 28 was significantly smaller in the eplerenone-treated mice than in controls (19.8 +/- 2.6%, n = 14, vs. 33.4 +/- 5.4%, n = 6, mean +/- SEM, P < 0.05). Gene expression of mouse mast cell proteases-4 and -5, matrix metalloproteinase-9, and type I procollagen on day 6 after EMC virus inoculation was significantly decreased in the hearts of eplerenone-treated mice. These results suggest that eplerenone has anti-inflammatory effects, and exerts its beneficial effects on viral myocarditis by suppression of genes related to mast cells and cardiac remodelling in the hearts of mice.
    No preview · Article · Feb 2009 · European Journal of Heart Failure